All Resources
telehealth prescribing peptides GLP-1 compliance

Telehealth Prescribing for Peptides and GLP-1: What Providers Need to Know

A complete guide to the regulatory environment for telehealth prescribing of compounded peptides and GLP-1 medications. Covers federal requirements, state-by-state considerations, the Ryan Haight Act, DEA rules, and practical compliance strategies for telehealth practices.

Karpa Health Team · · 12 min read
Disclaimer: This content is intended for healthcare professionals evaluating practice management solutions. It does not constitute medical advice.

Telehealth has transformed how medical practices deliver care, and for practices offering peptide therapy and GLP-1 weight loss programs, telehealth prescribing enables geographic reach that was previously impossible without multiple office locations.

However, telehealth prescribing operates within a complex regulatory framework that varies by state, medication type, and practice model. This guide covers what providers need to know about prescribing compounded peptides and GLP-1 medications via telehealth: the federal rules, state-by-state considerations, compliance requirements, and practical strategies for building a compliant telehealth prescribing practice.

Federal Regulatory Framework

The Ryan Haight Act

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 is the primary federal law governing online prescribing of controlled substances. Key provisions:

Critical distinction for peptide and GLP-1 practices: Most peptides (BPC-157, CJC-1295/Ipamorelin, Thymosin Alpha-1, GHK-Cu, TB-500) and GLP-1 medications (semaglutide, tirzepatide) are NOT controlled substances. The Ryan Haight Act does not apply to these medications.

The Ryan Haight Act becomes relevant if your program includes:

COVID-Era Telehealth Flexibilities and Their Evolution

During the COVID-19 public health emergency, the DEA issued temporary rules allowing controlled substance prescribing via telehealth without an initial in-person visit. These flexibilities have been extended multiple times.

Current status (as of early 2026):

The DEA has proposed permanent rules for telehealth prescribing of controlled substances. The proposed framework includes:

Check the DEA Diversion Control Division for the most current telehealth prescribing rules, as this area continues to evolve.

FTC and Prescribing Practices

The Federal Trade Commission has authority over deceptive practices in healthcare marketing. For telehealth prescribing practices, this means:

State-by-State Considerations

Licensure Requirements

The foundational rule for telehealth prescribing: you must be licensed in the state where the patient is physically located at the time of the consultation. This is not where the patient lives permanently or where they receive mail; it is where they are sitting during the telehealth visit.

Options for multi-state practice:

  1. Individual state licenses: Apply for licensure in each state where you want to treat patients. Most common approach for practices targeting specific markets.

  2. Interstate Medical Licensure Compact (IMLC): An agreement among 40+ participating states that provides an expedited pathway to licensure in multiple states. Physicians (MDs and DOs) can apply through the compact for licenses in member states. Does not eliminate the need for individual state licenses, but streamlines the application process.

  3. Nurse Practitioner Compact (APRN Compact): Similar to the IMLC but for advanced practice registered nurses. Fewer participating states currently, but growing.

  4. State-specific telehealth licenses: Some states offer limited telehealth-only licenses that allow out-of-state providers to treat patients in their state via telehealth without full licensure.

Patient-Provider Relationship Requirements

Each state defines what constitutes a valid patient-provider relationship for prescribing purposes. Common models:

Model 1: Synchronous video required

Model 2: Synchronous audio or video accepted

Model 3: Asynchronous (store-and-forward) accepted

Model 4: Initial in-person required

Prescribing Authority Variations

Beyond the patient-provider relationship, states differ on:

States with Notable Telehealth Frameworks

While a complete 50-state analysis is beyond the scope of this article, several states have particularly relevant frameworks:

Texas: Allows prescribing via telehealth after establishing a patient-provider relationship. The Texas Medical Board requires a documented evaluation but does not mandate video for all encounters.

Florida: Telehealth-friendly with a specific telehealth statute that allows registered telehealth providers to practice across state lines with appropriate registration.

California: Requires an appropriate prior examination (which can be via telehealth) before prescribing. The Medical Board of California provides specific telehealth guidance.

New York: Has specific telehealth prescribing rules through the Department of Health. Generally telehealth-friendly but requires establishment of patient-provider relationship.

DEA Registration Considerations

When DEA Registration Matters

For practices prescribing only non-controlled peptides and GLP-1 medications, DEA registration is not required for those specific prescriptions. However:

DEA and Telehealth-Specific Provisions

The DEA has specific requirements for practitioners prescribing controlled substances via telehealth:

For the most current DEA telehealth requirements, monitor the DEA’s telemedicine page and proposed rulemaking notices.

Compliance Framework for Telehealth Prescribing

Documentation Requirements

Every telehealth prescribing encounter should document:

  1. Patient identification verification: How you confirmed the patient’s identity (photo ID, prior relationship, verification service)
  2. Patient location: State where patient is physically located during the encounter
  3. Technology used: Video, audio, or platform name
  4. Clinical evaluation: History reviewed, symptoms assessed, clinical reasoning
  5. Prescribing rationale: Why the medication is appropriate for this patient
  6. Informed consent: Documented telehealth-specific consent
  7. Follow-up plan: Monitoring schedule, next appointment, how to reach provider

Telehealth-specific consent should address:

HIPAA Compliance for Telehealth

All telehealth encounters must occur on HIPAA-compliant platforms:

Consumer platforms (FaceTime, Zoom without healthcare plan, WhatsApp) are NOT HIPAA-compliant and should not be used for clinical telehealth encounters.

Practical Implementation

Building a Compliant Telehealth Workflow

Step 1: Determine your geographic scope

Step 2: Establish your telehealth technology

Step 3: Create state-specific protocols

Step 4: Train your team

Scheduling and Patient Management

Telehealth practices face unique scheduling considerations:

Video Conferencing Best Practices

For clinical telehealth encounters:

Karpa Health’s Telehealth Infrastructure

Karpa Health includes purpose-built telehealth capabilities for practices prescribing peptides and GLP-1 medications:

Built-In Video Conferencing

Calendar and Scheduling

State-Aware Compliance

Integrated Prescribing

Common Questions About Telehealth Prescribing

”Can I prescribe based on a questionnaire alone?”

This depends on your state’s definition of a patient-provider relationship. Some states require synchronous (real-time) interaction for initial prescriptions. Others may allow asynchronous prescribing under specific conditions. The safest approach is to conduct at least one synchronous video or audio consultation before initial prescribing, then use asynchronous communication for ongoing management and refills.

”What if my patient travels to another state?”

If a patient travels and needs a refill or dose adjustment, you can typically prescribe to them in the new state only if you are licensed there and the prescription meets that state’s telehealth rules. For maintenance prescriptions that are already established, most states allow continued prescribing as long as the patient-provider relationship was properly established.

”Do I need malpractice coverage for telehealth?”

Yes. Verify that your malpractice insurance covers telehealth encounters and all states where you practice. Many insurers now specifically address telehealth in their policies. You may need endorsements or separate coverage for multi-state telehealth practice.

”Can my NP or PA prescribe via telehealth independently?”

This depends entirely on state law. In full-practice-authority states, NPs can prescribe independently via telehealth. In restricted states, collaborative practice agreements may have specific telehealth provisions. PAs always need a supervisory relationship, though the nature of that supervision varies by state. The American Association of Nurse Practitioners maintains current state-by-state scope information.

Risk Mitigation Strategies

Avoid Common Compliance Pitfalls

  1. Never prescribe to a patient in a state where you are not licensed. Verify patient location at every encounter, not just the first one.

  2. Document the clinical rationale for every prescription. “Patient requested medication” is not sufficient clinical documentation. Document your clinical evaluation, assessment, and reasoning.

  3. Maintain proper supervision documentation. If NPs or PAs prescribe under collaborative agreements, ensure supervision requirements are met and documented per state rules.

  4. Keep consent current. Telehealth consent should be renewed periodically and whenever regulations change.

  5. Monitor regulatory changes. Telehealth rules are evolving rapidly. What was acceptable last year may not be compliant today. The Federation of State Medical Boards (FSMB) publishes regular updates on state telehealth policies.

Building Defensible Practice Patterns

The best protection against regulatory scrutiny is practicing good medicine:

Getting Started with Telehealth Prescribing

For practices ready to add telehealth prescribing for peptides and GLP-1 programs:

  1. Audit your current licensure and determine which states you can serve today
  2. Review state-specific rules for each state where you want to prescribe via telehealth
  3. Select a compliant platform that integrates telehealth, prescribing, and pharmacy routing (Karpa Health provides all three)
  4. Create your documentation templates for telehealth encounters
  5. Build state-specific consent forms as needed
  6. Train providers and staff on telehealth-specific compliance requirements
  7. Launch with a limited geographic scope and expand as you verify compliance in each state

Telehealth prescribing for peptides and GLP-1 medications is one of the most efficient ways to grow a cash-pay practice beyond your local market. The regulatory framework is manageable when you understand the rules and build compliant workflows from the start.

Visit our FAQ for additional questions about telehealth prescribing, or explore how Karpa Health’s integrated peptide and GLP-1 platforms support compliant telehealth practice.

For practices building telehealth programs, you may also find these resources helpful: HIPAA compliance for cash-pay programs covers privacy requirements for digital health delivery, and our direct-to-patient pharmacy fulfillment guide explains how shipping logistics work when patients are not local. Karpa integrates with pharmacy partners like Empower Pharmacy for streamlined telehealth-to-fulfillment workflows.

Telehealth lets us serve patients across the state without the overhead of multiple office locations. Karpa's built-in video and scheduling made compliance straightforward.
Dr. R · Telehealth Practice Owner, Texas

Frequently Asked Questions

Do I need a DEA registration to prescribe peptides via telehealth?
For most peptides (BPC-157, CJC-1295/Ipamorelin, Thymosin Alpha-1), no. These are not controlled substances and do not require DEA registration to prescribe. However, if your program includes testosterone (Schedule III) or any other controlled substance, you need an active DEA registration. GLP-1 medications like semaglutide and tirzepatide are also not controlled substances and do not require DEA registration.
Can I prescribe to patients in other states via telehealth?
You can only prescribe to patients in states where you hold an active medical license. Most states require the prescriber to be licensed in the state where the patient is physically located at the time of the consultation. Some states offer telehealth-specific licenses or interstate compacts (like the Interstate Medical Licensure Compact) that simplify multi-state practice.
What constitutes a valid patient-provider relationship for telehealth prescribing?
Requirements vary by state, but generally you must: conduct a real-time clinical evaluation (synchronous audio or video), review the patient's medical history, make a clinical determination that the medication is appropriate, document your clinical findings, and be available for follow-up. Most states accept video consultations as sufficient to establish the relationship. Some states still require an initial in-person visit for certain medications.
Are there specific telehealth consent requirements?
Yes. Most states require specific telehealth informed consent that covers: the nature and limitations of telehealth, that the visit is conducted remotely, the patient's right to refuse telehealth and seek in-person care, privacy and security measures, technical requirements, and billing information. This consent should be documented separately from general medical consent.
What happens if telehealth rules change in my state?
Telehealth regulations are evolving rapidly. States frequently update their telehealth prescribing rules, especially following COVID-era expansions. Best practice is to monitor your state medical board website regularly, subscribe to regulatory update services, and work with a platform like Karpa Health that tracks regulatory changes and updates compliance workflows accordingly. The Federation of State Medical Boards (FSMB) maintains a telehealth policy tracker at fsmb.org.

Disclaimer: This article is for informational purposes only and does not constitute medical, legal, or regulatory advice. Always consult qualified professionals for clinical, legal, or compliance decisions specific to your practice. Content is reviewed periodically but may not reflect the most recent changes in regulations or guidelines.

Ready to Launch Your Program?

Book a demo and we'll show you exactly how Karpa works for your practice. Most teams go live in under two weeks.

Book a Demo